title: Overview: New Modality for Cancer Treatment.
abstract: Cancer immunotherapy is now becoming a promising modality of cancer treatment upon the clinical successes of adoptive T-cell transfer and immune checkpoint blockade. At the 30th Nagoya International Cancer Treatment Symposium, Marcel R.M. van den Brink (Memorial Sloan Kettering Cancer Center, MSKCC, New York, N.Y., USA) showed novel strategies to control malignant relapse and graft-versus-host disease, both major obstacles for clinical benefits in allogeneic hematopoietic stem cell transplantation. Alexander M. Lesokhin (MSKCC, New York, N.Y., USA) presented an overview of immune checkpoint blockade, particularly focusing on hematologic malignancies stressing the importance of immunomonitoring to identify biomarkers.
authors.affiliation: Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Nishikawa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D006086:Graft vs Host Disease / Q000276:immunology* / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007157:Immunologic Surveillance; D016219:Immunotherapy, Adoptive; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents